Bivalirudin
Generic Name: bivalirudin
Brand Names:
Bivalirudin
Bivalirudin is a synthetic 20 amino acid peptide that acts as a specific, reversible direct thrombin inhibitor. It is indicated as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia.
Overview
Bivalirudin is a synthetic 20 amino acid peptide that acts as a specific, reversible direct thrombin inhibitor. It is indicated as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia.
Uses
Indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
Dosage
Initial intravenous bolus of 0.75 mg/kg followed by 1.75 mg/kg/h infusion during the procedure. Additional 0.3 mg/kg bolus may be given at 5 minutes post-initial dose if needed based on activated clotting time.
Side Effects
Most common adverse reaction is bleeding. Major bleeding events occurred in 3.7% of patients. Postmarketing reports include fatal bleeding, hypersensitivity reactions, anaphylaxis, and thrombus formation.
Interactions
Coadministration with heparin, warfarin, thrombolytics, or GPIs is associated with increased major bleeding risk compared to non-concomitant use.
Warnings
Bivalirudin increases the risk of bleeding. Increased acute stent thrombosis in STEMI patients. Thrombotic risk with coronary artery brachytherapy. Closely monitor elderly patients. Contraindicated in active major bleeding and hypersensitivity to bivalirudin.
Pregnancy
There are no data available on use of bivalirudin in pregnant women, though animal studies showed no fetal harm at recommended doses.
Storage
Store at controlled room temperature 20 to 25 degrees C (68 to 77 degrees F). Reconstituted material may be stored refrigerated for up to 24 hours.
Frequently Asked Questions
What is Bivalirudin used for?▼
Indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
What are the side effects of Bivalirudin?▼
Most common adverse reaction is bleeding. Major bleeding events occurred in 3.7% of patients. Postmarketing reports include fatal bleeding, hypersensitivity reactions, anaphylaxis, and thrombus formation.
Can I take Bivalirudin during pregnancy?▼
There are no data available on use of bivalirudin in pregnant women, though animal studies showed no fetal harm at recommended doses.
What are the important warnings for Bivalirudin?▼
Bivalirudin increases the risk of bleeding. Increased acute stent thrombosis in STEMI patients. Thrombotic risk with coronary artery brachytherapy. Closely monitor elderly patients. Contraindicated in active major bleeding and hypersensitivity to bivalirudin.
Related Medications
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.